Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00877292




Registration number
NCT00877292
Ethics application status
Date submitted
6/04/2009
Date registered
6/04/2009
Date last updated
1/06/2015

Titles & IDs
Public title
A New Prenatal Blood Test for Down Syndrome
Scientific title
The RNA (RNA-Based Noninvasive Aneuploidy) Study
Secondary ID [1] 0 0
09-0004
Universal Trial Number (UTN)
Trial acronym
RNA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Down Syndrome 0 0
Trisomy 21 0 0
Condition category
Condition code
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above
Human Genetics and Inherited Disorders 0 0 0 0
Down's syndrome
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Down syndrome - Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The RNA study is an observational trial whose primary aim is to document the performance (sensitivity and specificity) of a laboratory developed test (LDT), using fetal nucleic acid in maternal plasma to identify Down syndrome in early pregnancy.
Timepoint [1] 0 0
Within 1st and 2nd trimesters
Secondary outcome [1] 0 0
The secondary aim is to develop a sample bank to allow documentation of subsequent improvements in the existing LDT or documenting performance of new methodologies.
Timepoint [1] 0 0
Late1st and early 2nd trimesters

Eligibility
Key inclusion criteria
- Pregnant women between about 10 weeks and 21 weeks 6 days gestation who are undergoing
a diagnostic procedure (i.e., chorionic villus sampling or amniocentesis) for
karyotype analysis who have, on average, a high prevalence of Down syndrome (about
1:30 to 1:50).

- Three main sources are pregnancies screen positive for:

1. the combined test at 10 to 13 weeks (NT, PAPP-A and hCG)

2. the second trimester quadruple test at 15 to 18 weeks gestation

3. integrated screening (PAPP-A and the quadruple test, with or without NT).

- Variations of the integrated test such as sequential testing will also be acceptable.

- Other, less common high risk groups would be women having diagnostic testing because
of maternal age of 38 years or older at delivery, pregnancies with an abnormal
ultrasound highly suggestive of a chromosome abnormality (e.g., major heart defect,
clenched fist), and women with an inherited form of Down syndrome (Robertsonian
translocation).
Minimum age
18 Years
Maximum age
No limit
Gender
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Nonpregnant women and women at relatively low risk for a Down syndrome baby.

Study design
Purpose
Duration
Cross-sectional
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
University of Sydney - St. Leonards
Recruitment postcode(s) [1] 0 0
2065 - St. Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Rhode Island
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Utah
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
British Columbia
Country [15] 0 0
Canada
State/province [15] 0 0
Nova Scotia
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
Czech Republic
State/province [17] 0 0
Zlinsky kraj
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Ceske Budejovice
Country [19] 0 0
Hungary
State/province [19] 0 0
Budapest
Country [20] 0 0
Hungary
State/province [20] 0 0
Pecs
Country [21] 0 0
Ireland
State/province [21] 0 0
Dublin
Country [22] 0 0
Israel
State/province [22] 0 0
Haifa
Country [23] 0 0
Italy
State/province [23] 0 0
Genova
Country [24] 0 0
Spain
State/province [24] 0 0
Catalonia

Funding & Sponsors
Primary sponsor type
Other
Name
Women and Infants Hospital of Rhode Island
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Sequenom, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The study will examine the sensitivity and specificity of a circulating cell-free nucleic
acid test (DNA/RNA) to identify Down syndrome between about 10 weeks and 21 weeks 6 days
gestation. In addition, the new test may be used to identify trisomy 13 and 18 as part of a
more complete laboratory developed test. We hypothesize that the new circulating cell-free
fetal NA-based test will accurately and precisely measure specific fetal markers in maternal
circulation and that measurement will lead to the ability to noninvasively identify with high
sensitivity and specificity, fetal chromosome abnormalities, such as Down syndrome.
Trial website
https://clinicaltrials.gov/show/NCT00877292
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Barbara O'Brien, MD
Address 0 0
Women and Infants Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications